Drug Profile

ICP 923

Alternative Names: ICP-054; ICP-923; ZB-021

Latest Information Update: 21 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator InnoCare Pharma
Developer InnoCare Pharma; Zenas BioPharma
Class Anti-inflammatories; Small molecules
Mechanism of Action Interleukin 17 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Autoimmune disorders
Preclinical Inflammation

Most Recent Events

13 May 2026 Phase-I clinical trials in Autoimmune disorders (In volunteers) in China (PO)
13 May 2026 Pharmacodynamics and adverse events data from a preclinical trial in Autoimmune disorders and Inflammation released by InnoCare Pharma
13 May 2026 Zenas BioPharma plans a proof of concept clinical trial for Psoriasis in North America

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com